Literature DB >> 7511394

Antigenic variation in gp120s from molecular clones of HIV-1 LAI.

J P Moore1, H Yoshiyama, D D Ho, J E Robinson, J Sodroski.   

Abstract

To address the relationship between primary sequence variation in HIV-1 gp120 and its antigenic structure in a simple system, we have measured the binding of human and murine monoclonal antibodies (MAbs) to gp120 from four molecular clones of HIV-1 LAI: HxB2, HxB3, Hx10, and NL4-3. Despite the close relationship between these clones, and their relatively conserved gp120 sequences, there is considerable variation in their antigenic structure, judged by MAb reactivities to the V2, V3, and C4 domains and to discontinuous epitopes. Because of our prior studies of the determinants of MAb binding to HxB2 gp120, we can make reasonable estimates of how sequence variation among the LAI clone gp120s affects their binding of some MAbs; for other MAbs our current knowledge of gp120 structure is too limited to allow such estimates. These results indicate that small variations in primary gp120 amino acid sequence can profoundly affect recognition of this glycoprotein by all five groups of defined anti-gp120 neutralizing antibodies.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7511394     DOI: 10.1089/aid.1993.9.1185

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  15 in total

1.  Truncation of the cytoplasmic domain induces exposure of conserved regions in the ectodomain of human immunodeficiency virus type 1 envelope protein.

Authors:  Terri G Edwards; Stéphanie Wyss; Jacqueline D Reeves; Susan Zolla-Pazner; James A Hoxie; Robert W Doms; Frédéric Baribaud
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

2.  Stabilized HIV-1 envelope glycoprotein trimers lacking the V1V2 domain, obtained by virus evolution.

Authors:  Ilja Bontjer; Mark Melchers; Dirk Eggink; Kathryn David; John P Moore; Ben Berkhout; Rogier W Sanders
Journal:  J Biol Chem       Date:  2010-09-08       Impact factor: 5.157

3.  Sequential CD4-coreceptor interactions in human immunodeficiency virus type 1 Env function: soluble CD4 activates Env for coreceptor-dependent fusion and reveals blocking activities of antibodies against cryptic conserved epitopes on gp120.

Authors:  K Salzwedel; E D Smith; B Dey; E A Berger
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

4.  Study of the dynamics of neutralization escape mutants in a chimpanzee naturally infected with the simian immunodeficiency virus SIVcpz-ant.

Authors:  P N Nyambi; P Lewi; M Peeters; W Janssens; L Heyndrickx; K Fransen; K Andries; M Vanden Haesevelde; J Heeney; P Piot; G van der Groen
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

5.  Sequences in glycoprotein gp41, the CD4 binding site, and the V2 domain regulate sensitivity and resistance of HIV-1 to broadly neutralizing antibodies.

Authors:  Sara M O'Rourke; Becky Schweighardt; Pham Phung; Kathryn A Mesa; Aaron L Vollrath; Gwen P Tatsuno; Briana To; Faruk Sinangil; Kay Limoli; Terri Wrin; Phillip W Berman
Journal:  J Virol       Date:  2012-08-29       Impact factor: 5.103

6.  Enfuvirtide resistance mutations: impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization.

Authors:  Jacqueline D Reeves; Fang-Hua Lee; John L Miamidian; Cassandra B Jabara; Marisa M Juntilla; Robert W Doms
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

7.  An altered and more efficient mechanism of CCR5 engagement contributes to macrophage tropism of CCR5-using HIV-1 envelopes.

Authors:  Jasminka Sterjovski; Michael Roche; Melissa J Churchill; Anne Ellett; William Farrugia; Lachlan R Gray; Daniel Cowley; Pantelis Poumbourios; Benhur Lee; Steven L Wesselingh; Anthony L Cunningham; Paul A Ramsland; Paul R Gorry
Journal:  Virology       Date:  2010-06-08       Impact factor: 3.616

8.  Phorbol ester-induced down modulation of tailless CD4 receptors requires prior binding of gp120 and suggests a role for accessory molecules.

Authors:  H Golding; D S Dimitrov; J Manischewitz; C C Broder; J Robinson; S Fabian; D R Littman; C K Lapham
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

9.  Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F, and I: lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent infectivity enhancement.

Authors:  L G Kostrikis; Y Cao; H Ngai; J P Moore; D D Ho
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

10.  Humoral response to oligomeric human immunodeficiency virus type 1 envelope protein.

Authors:  T M Richardson; B L Stryjewski; C C Broder; J A Hoxie; J R Mascola; P L Earl; R W Doms
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.